FNDC5 and type 2 diabetes mellitus: In T2D patients with moderate glycemic control status, the current circulating miRNAs, miR-146a and miR-144; myokines, adropin and irisin; and serum OPN yielded a range of 76.2-91.5% specificity and 71.6–89.4% sensitivity.